Please login to the form below

Not currently logged in
Email:
Password:

Rybelsus

This page shows the latest Rybelsus news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

By taking Rybelsus first, people with type 2 diabetes, in conjunction with their care teams, are now able to utilise this medicine early in their diabetes treatment journeys.”. ... The FDA’s 2019 decision on Rybelsus was based on the results from ten

Latest news

More from news
Approximately 5 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • On our best behaviour On our best behaviour

    Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...